LENZ Therapeutics Inc

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Del Mar, CA.

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President and CEO Dr. Marc Odrich - Chief Medical Officer Shawn Olsson - Chief Commercial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Yigal Nochomovitz - Citigroup Tim Lugo - William Blair Basma Radwan - Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to LENZ Therapeutics First Quarter 2024 Financial Results and Business Update.

LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced positive topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly.

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, r.

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Comstock Resources

Liberty Media Corp-Liberty SiriusXM

Nkarta, Inc.

Sirius XM Hlds

Snowflake

ARS Pharmaceuticals Inc

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Graphite Bio

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced the completion of its previously announced merger with Graphite Bio, Inc. (previously trading on Nasdaq under the ticker symbol “GRPH”) (“Graphite Bio”). The new combined company will operate under the name LENZ Thera.

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

News for LENZ Therapeutics Inc Stock (LENZ)